#2 - ANI Pharmaceuticals (NASDAQ:ANIP)
ANI Pharmaceuticals (NASDAQ: ANIP) - ANI Pharmaceuticals has a lot going in its favor. ANIP is known for developing a growing number of generic and branded therapies. Since 2014, the company has more than quadrupled the number of products it has on the market and in the process has also increased its revenue from $56 million to over $200 million in 2018. However, while revenue can be a misleading indicator, it's hard to ignore the company's corresponding growth in EBITDA (earnings before interest, taxes, depreciation, and amortization). And with an annual market size of $3.3 billion, it's easy to see why the company is poised for growth in 2019 and beyond. In fact, despite the 20% drop in their stock price in the trailing year, they are projecting annual earnings growth between 10-15% between now and 2021. The company has a P/E ratio that is under 10 and is currently trading solidly between its 52-week high and low.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More - Current Price
- $55.76
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $77.33 (38.7% Upside)
